Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study

被引：0

作者：

Younes, A. ^{[1
]}

Andreadis, C. ^{[2
]}

Assouline, S. ^{[3
]}

Rizzieri, D. ^{[4
]}

Wedwood, A. ^{[1
]}

McLaughlin, P. ^{[1
,5
]}

Laille, E.

Li, Z. ^{[6
]}

Martell, R. E. ^{[6
]}

Crump, M. ^{[7
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Penn, Philadelphia, PA 19104 USA

[3] Sir Mortimer B Davis Jewish Hosp, Montreal, PQ, Canada

[4] Duke Univ, Med Ctr, Durham, NC 27706 USA

[5] Pharmion Corp, Phamaco & PK, Boulder, CO USA

[6] MethylGene Inc, Drug Dev, Montreal, PQ, Canada

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：162 / 162

页数：1